Celula is focused on advancing prenatal diagnostics through innovative noninvasive testing solutions. The company is developing a fully noninvasive prenatal genetic diagnostic test that aims to improve the Positive Predictive Value (PPV) for all women, including those in low-risk populations. Current chromosome aneuploidy tests are primarily endorsed for high-risk women, and they often require invasive procedures like amniocentesis for definitive diagnosis after a positive screening. Celula's approach involves isolating fetal cells from maternal circulation, which could lead to a more accurate and safer testing paradigm, reducing the need for invasive confirmations and minimizing the risk of complications such as miscarriages.

In addition to prenatal diagnostics, Celula is also exploring novel approaches to cancer detection, specifically targeting earlier detection of ovarian cancer. The company emphasizes the importance of advancing the accuracy of women's diagnostics through research and development partnerships. By focusing on these areas, Celula aims to enhance the overall effectiveness of diagnostic tools available for women, ultimately leading to better health outcomes and more accessible testing options.

United States

Celula is a biotechnology company that offers Celula IDA, Integrated Diagnostic Accuracy, providing better solutions for prenatal testing and novel approaches to cancer detection.

Celula

Company Details